MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


0026-895X/04/6505-1148-1158$20.00
Mol Pharmacol 65:1148-1158, 2004

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wang, H.
Right arrow Articles by Zeldin, D. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wang, H.
Right arrow Articles by Zeldin, D. C.

Cloning, Expression, and Characterization of Three New Mouse Cytochrome P450 Enzymes and Partial Characterization of Their Fatty Acid Oxidation Activities

Hong Wang, Yun Zhao, J. Alyce Bradbury, Joan P. Graves, Julie Foley, Joyce A. Blaisdell, Joyce A. Goldstein , and Darryl C. Zeldin

Laboratories of Respiratory Biology (H.W., Y.Z., J.A.B., J.P.G., D.C.Z.), Pharmacology and Chemistry (H.W., J.A.B., J.A.G.), and Experimental Pathology (J.F.), National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, North Carolina

The mammalian CYP2C subfamily is one of the largest and most complicated in the cytochrome P450 superfamily. In this report, we describe the organization of the mouse Cyp2c locus, which contains 15 genes and four pseudogenes, all of which are located in a 5.5-megabase region on chromosome 19. We cloned three novel mouse CYP2C cDNAs (designated CYP2C50, CYP2C54, and CYP2C55) from mouse heart, liver, and colon, respectively. All three cDNAs contain open reading frames that encode 490 amino acid polypeptides that are 57 to 95% identical to other CYP2Cs. The recombinant CYP2C proteins were expressed in Escherichia coli after N-terminal modification, partially purified, and shown to be active in the metabolism of both arachidonic acid (AA) and linoleic acid, albeit with different catalytic efficiencies and profiles. CYP2C50 and CYP2C54 metabolize AA to epoxyeicosatrienoic acids (EETs) primarily, and linoleic acid to epoxyoctadecenoic acids (EOAs) primarily, whereas CYP2C55 metabolizes AA to EETs and hydroxyeicosatetraenoic acids and linoleic acid to EOAs and hydroxyoctadecadienoic acids. Northern blotting and reverse transcription-polymerase chain reaction analysis reveal that CYP2C50 transcripts are abundant in liver and heart; CYP2C54 transcripts are present in liver, kidney, and stomach; and CYP2C55 transcripts are abundant in liver, colon, and kidney. Immunoblotting studies demonstrate that CYP2C50 protein is expressed in liver and heart, CYP2C54 protein is detected primarily in liver, and CYP2C55 protein is present primarily in colon. Immunohistochemistry reveals that CYP2C55 is most abundant in surface columnar epithelium in the cecum. We conclude that these new CYP2C enzymes are probably involved in AA and linoleic acid metabolism in mouse hepatic and extrahepatic tissues.


Received November 21, 2003; accepted February 17, 2004.

Address correspondence to: Dr. Joyce A. Goldstein, National Institute of Environmental Health Sciences, 111 T.W. Alexander Drive, Building 101, Room A323, Research Triangle Park, NC 27709. E-mail: goldste1{at}niehs.nih.gov




This article has been cited by other articles:


Home page
Cardiovasc ResHome page
C. M. Jenkins, A. Cedars, and R. W. Gross
Eicosanoid signalling pathways in the heart
Cardiovasc Res, May 1, 2009; 82(2): 240 - 249.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
R. A. B. van Waterschoot, A. E. van Herwaarden, J. S. Lagas, R. W. Sparidans, E. Wagenaar, C. M. M. van der Kruijssen, J. A. Goldstein, D. C. Zeldin, J. H. Beijnen, and A. H. Schinkel
Midazolam Metabolism in Cytochrome P450 3A Knockout Mice Can Be Attributed to Up-Regulated CYP2C Enzymes
Mol. Pharmacol., March 1, 2008; 73(3): 1029 - 1036.
[Abstract] [Full Text] [PDF]


Home page
Toxicol PatholHome page
W. O. Ward, D. A. Delker, S. D. Hester, S.-F. Thai, D. C. Wolf, J. W. Allen, and S. Nesnow
Transcriptional Profiles in Liver from Mice Treated with Hepatotumorigenic and Nonhepatotumorigenic Triazole Conazole Fungicides: Propiconazole, Triadimefon, and Myclobutanil
Toxicol Pathol, December 1, 2006; 34(7): 863 - 878.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
J. P. Jackson, S. S. Ferguson, M. Negishi, and J. A. Goldstein
Phenytoin Induction of the Cyp2c37 Gene Is Mediated by the Constitutive Androstane Receptor
Drug Metab. Dispos., December 1, 2006; 34(12): 2003 - 2010.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
H. Obinata, T. Hattori, S. Nakane, K. Tatei, and T. Izumi
Identification of 9-Hydroxyoctadecadienoic Acid and Other Oxidized Free Fatty Acids as Ligands of the G Protein-coupled Receptor G2A
J. Biol. Chem., December 9, 2005; 280(49): 40676 - 40683.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Gastrointest. Liver Physiol.Home page
P. R. Kiela, A. J. Midura, N. Kuscuoglu, S. D. Jolad, A. M. Solyom, D. G. Besselsen, B. N. Timmermann, and F. K. Ghishan
Effects of Boswellia serrata in mouse models of chemically induced colitis
Am J Physiol Gastrointest Liver Physiol, April 1, 2005; 288(4): G798 - G808.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
T. C. DeLozier, C.-C. Tsao, S. J. Coulter, J. Foley, J. A. Bradbury, D. C. Zeldin, and J. A. Goldstein
CYP2C44, a New Murine CYP2C That Metabolizes Arachidonic Acid to Unique Stereospecific Products
J. Pharmacol. Exp. Ther., September 1, 2004; 310(3): 845 - 854.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2004 by the American Society for Pharmacology and Experimental Therapeutics